2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Рекомендации ESC/EAS 2019 года по ведению пациентов с дислипидемиями: модификация липидов для снижения сердечно-сосудистого риска
2019-08-31
SCID: 54.1/b32rpmmp
Discuss with AI
ESC/EAS Guidelinescardiovascular risk reductiondyslipidaemia managementlipid modificationpreventive strategies
Figures from the paper
Abstract (AI)
The ESC/EAS Guidelines represent the views of the ESC and EAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication.The ESC and EAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/EAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies.Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/EAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver.Nor do the ESC/EAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations.It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Key Findings
1
Healthcare professionals should reconcile the guidelines with updated official public-health recommendations and applicable drug and medical-device regulations.
2
The 2019 ESC/EAS Guidelines address lipid modification strategies intended to reduce cardiovascular risk.
3
The guidelines are based on the scientific and medical evidence available at the time of publication.
4
The recommendations support clinical decision-making for preventive, diagnostic, and therapeutic management of dyslipidaemias, while preserving individualized professional judgment.
Research Object
Management of dyslipidaemias (lipid modification interventions to reduce cardiovascular risk)
Research Subject
lipid modification strategies to reduce cardiovascular risk
Publication Details
Publication Date
2019-08-31
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by7
Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: A Cohort Study2024
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk2022
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention2025
LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study2024
Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry2025
Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US2024
Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in France2025